Introduction
Large registry-based clinical studies have demonstrated that a higher number of myocardial infarctions occur early in the day. [1] [2] [3] [4] Different explanations for this phenomenon have been proposed, such as an increase in catecholamine and a higher platelet activity [5] [6] [7] [8] [9] at this time of the day. Interestingly, data suggest that circadian variations in platelet activity continue even during the use of antiplatelet agents. Indeed, it has been shown that platelet inhibition in patients with ST-segment elevation myocardial infarction (STEMI) treated with aspirin and clopidogrel continued to vary, although with less inhibition, during the midmorning hours. 10 In addition, a post hoc analysis of the TRITON-TIMI 38 trial 11 showed a higher rate of stent thrombosis in the early part of the day in patients undergoing dual antiplatelet therapy with aspirin and prasugrel. 12 However, no data exist regarding any circadian variation in platelet inhibition associated with ticagrelor, which is the oral antiplatelet agent recommended by the European Society of Cardiology guidelines, with a broader indication in the context of ORIGINAL ARTICLE 14 wellstudied in non-STEMI patients 15 and worldwide used. 16 This study was therefore designed to assess any potential circadian variation in ticagrelor-induced platelet inhibition using an experimental model involving healthy volunteers.
Materials and methods

Recruitment
Participants were recruited using advertisements. Their medical history was carefully analysed and physical exam was performed.
Inclusion and exclusion criteria
The two inclusion criteria were to be more than 18 years old and to have signed the informed consent with discernment. The study's exclusion criteria included: (i) anaemia; (ii) presence of any kidney; and (iii) previous history of a cardiovascular event, a cerebrovascular accident, peripheral vascular disease, a chronic or acute inflammatory, metabolic, autoimmune, rheumatic, or endocrine disease, or any other condition requiring daily medication. At inclusion, participants underwent routine blood testing, including electrolytes, haemoglobin, and platelets in order to confirm the absence of any abnormality.
Protocol and standardization
On the day of the experiment, standardized meals validated by dieticians were provided at 09:00, 13:00, and 19:00. Standardized physical activity involved a 10-min walk before and after every meal. During the rest of the day, participants were free to move about in the hospital but were forbidden to eat and do any sporting activities. Participants were asked to be in bed at 21:00 and lights went out at 22:00. It is of note that the volunteers were asked to follow this schedule for seven consecutive days prior to the study. An antebrachial venous catheter was placed on each of the 25 healthy participants (non-dominant arm) in order to take a blood sample every 4 h (Figure 1 ). To avoid disturbances of their sleep, night-time blood samples were taken in the dark using special equipment (extension lines and low-intensity torches). The quality of their circadian rhythms was assessed by measuring their heart rate, arterial blood pressure on the dominant arm (two measures each time with oscillatory measurements), and body temperature 17 (using an infrared ear thermometer)
before each blood sample.
Laboratory
To avoid any bias related to a circadian variation in ticagrelor absorption or to diet-mediated CYP3A4 effects, 18 ticagrelor-induced platelets inhibition was performed in vitro. For each subject, 72 h before starting the protocol and at the same hour of the day (16:00), ticagrelor was added to blood in vitro and its potency was assessed 10 min later by calculating the concentration that provided 50% inhibition of the maximum response (IC50) using the Ultegra-Rapid Platelet Function Analyser and VerifyNow P2Y12 assay cartridges Accriva (San Diego, CA, USA). 19 On the study day, the ticagrelor IC50 concentration previously determined was added in vitro to each blood sample after each blood sample. The percentage of platelet inhibition (relative to a control channel containing a thrombin receptor-activating peptide) was recorded. Platelet count was measured in each volunteer's first blood sample and then every 4 h for a subgroup of six volunteers in order to exclude any bias. 20 In another subgroup of six volunteers, variability in the platelet response in the absence of ticagrelor was measured every 4 h.
At 30-45 min after blood sampling, von Willebrand activity was measured in citrated plasma with an automated immunoturbidimetric assay (INNOVANCE V R VWF Ac, Siemens Healthcare Diagnostic, Marburg, Germany) on a CS-5100 analyser (Sysmex Corporation, Kobe, Japan distributed by Siemens AG, Switzerland). Briefly, the INNOVANCE V R VWF Ac assay makes use of a recombinant glycoprotein lb (GPIb) protein with two gain of function mutations, that binds von Willebrand factor in absence of ristocetin. At the same time recombinant GPIb binds to polystyrene particles coated with an anti-GPIb antibody. The von Willebrand factor dependent-agglutination of microparticles is than detected turbidimetrically. Standard curves (low range 2-25% and medium range 15-180% of norm) were generated by automatic determination of different dilution of Standard Human Plasma and Dade V R Owren's Veronal buffer (Siemens Healthcare Diagnostic, Marburg, Germany), following the manufacturer's recommendations.
Ethics and disclosure
This study was carried out in accordance with the recommendations the Human Research Ethical Committee of the Canton Vaud, Switzerland with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Human Research Ethical Committee of the Canton Vaud, Switzerland.
Statistical analysis
Statistical analysis was conducted using the SPSS version 24 (IBM SPSS Statistics, IBM Corporation, Armonk, NY, USA) and figures were generated using the Graphpad Prism v.6.0d (Graphpad Software). Descriptive results are expressed as a number of participants and percentage, average ± standard deviation, or as median and interquartile range. To determine whether heart rate, arterial blood pressure, body temperature, percentage of ticagrelor-induced platelet inhibition, von Willebrand activity, and platelet count were dependent on the time of sampling, periodic sinusoidal regression analyses were performed using the following equation: f(t) = a þ b * sin (2 pi * (t -c)/24) as previously proposed by Reiter et al. 21 Here, a indicates the midline estimating statistic of rhythm (MESOR, a measure of the rhythm-adjusted mean value), b indicates the amplitude, and c indicates the origin of the curve. Circadian rhythm was 
Results
Baseline clinical characteristics
Of the 25 volunteers, 11 were female and 14 were male. Mean age was 24.3 ± 2.6 years old.
Physiological parameters
Heart rate, systolic arterial blood pressure, diastolic blood pressure, and body temperature according to sampling time were fitted to sinusoidal regression lines, as shown in Figure 2 . Statistically significant circadian rhythms were found for all of the parameters studied (heart rate, P < 0.001; systolic arterial blood pressure, P < 0.002; diastolic arterial blood pressure, P < 0.001; body temperature, P < 0.001 tively. The lowest and highest values-based on the sinusoidal regression-were observed at 02:00/14:00 (heart rate), 01:00/14:00 (systolic arterial blood pressure); 01:00/13:00 (diastolic arterial blood pressure), and 05:00/20:00 (body temperature).
Platelet inhibition and von Willebrand activity
The percentage of ticagrelor-induced platelet inhibition, von Willebrand activity, and platelet count were fitted to sinusoidal regressions according to sampling time and are presented in Figure 3A -C, respectively. The percentage of ticagrelor-induced platelet inhibition plotted against time followed a circadian pattern (P < 0.001). The absolute amplitude of that inhibition was 3.80%, representing a relative variation of 8.76% according to the mean daytime inhibition values (MESOR = 43.39%). Based on the fitted sinusoidal regression, the lowest and highest percentages of ticagrelor-induced platelet inhibition were observed at 13:00 and 02:00, respectively. The results were comparable between females and males. Indeed, in female, the absolute amplitude of inhibition was 3.08% (for a mean daytime inhibition of 44.62%) whereas in male, the absolute amplitude of inhibition was 4.43% (for a mean daytime inhibition of 42.34%). In the subgroup of patients not treated with ticagrelor, the percentage of platelet inhibition also exhibited a circadian rhythm with the same pattern shifter to lower values (P < 0.001; Figure 4) . Moreover, von Willebrand activity also followed a similar circadian pattern (P < 0.001), with an absolute amplitude of 12.24% representing a relative variation of 14.05% according to the mean daytime von Willebrand activity (MESOR = 87.12%). Based on the fitted sinusoidal regression, the minimum and maximum values for von Willebrand activity were observed at 00:00 and at 12:00, respectively. A circadian variation in platelet count was observed (P < 0.001), with an absolute amplitude of 21.65 G/L, representing a relative variation of 8% according to the mean daytime platelet count (MESOR = 270.4 G/L). Minimum and maximum platelet counts were observed at 06:00 and at 20:00, respectively.
Discussion
To the best of our knowledge, this study is the first to demonstrate a circadian variation in ticagrelor-induced platelet inhibition. Interestingly, this significant circadian variation in platelet inhibition maintains the same pattern with or without treatment with ticagrelor, but the variation shifts towards a higher value after treatment. In other terms, despite the presence of the drug, platelets continue to exhibit higher reactivity in the late morning.
Chronotherapy using antiplatelet agents such as aspirin has been studied before. One recent study of 133 patients who were randomized to take 100 mg aspirin on awakening or at bedtime, demonstrated that bedtime aspirin intake reduced platelet reactivity during morning hours. 22 In another recent, randomized, open-label, crossover study comprising 30 outpatients with cardiovascular disease treated using aspirin, the authors also concluded that the level of platelet inhibition was statistically different when comparing morning and evening regimens. 23 However, as opposed to our study, the data from those studies do not allow firm conclusions to be drawn about the difference between a potential circadian variation in aspirin absorption and a circadian variation in aspirin-induced platelet inhibition. Furthermore, as the composition of meals was not the same during the day, factors related to food ingestion could also have led to differences in aspirin absorption. 24 One of the unique features of this study was that its design excluded bias due to food interactions or due to potential circadian variations in ticagrelor absorption. Furthermore, the study's design not only allowed a comparison between two drug administration times but also an analysis of ticagrelor's efficacy at any time of the day, therefore allowing a true circadian analysis. Different authors have suggested that the existence of a morning peak in the frequency of myocardial infarction should be taken into account when determining the best time for administering medication. 25 Indeed, some 23 have suggested that aspirin intake in the evening might provide better protection against ischaemic events. We feel that there is not yet enough evidence to firmly back this conclusion. It is of note that the differences observed are small, as in this study, and at present there is no data to indicate that such small differences could influence the occurrence of myocardial infarction or, more importantly, have an impact on outcomes, even if this 3.8% of absolute variation is maybe not totally negligible when compared with the 15% of variation in platelets inhibition over a period of 12 h following ticagrelor administration in STEMI patients. 26 Furthermore, in contrast to aspirin or other antiplatelet agents, such as clopidogrel, ticagrelor is administrated twice a day, and thus the question is not one of determining the best timing for administration but rather to investigate whether a higher morning dose would allow more stable platelet inhibition throughout the day. Further research in this direction needs to be performed.
Limitations
In parallel to the circadian variation in platelet aggregability, different studies have demonstrated that platelet count also exhibits a significant circadian rhythm 27, 28 which could be a source of bias. However, as in this study the highest number of platelets were observed in the afternoon and, therefore, we cannot suppose that ticagrelor exposure was less important in the morning. The number of subjects involved in this study was small, the smoking status was not documented, and they were young, not representative of a population with a high probability of acute coronary syndrome. 29 However, all them were in good health and the robustness of the study design allowed a physiological observation without any bias. Finally, this study was performed in vitro using IC50 concentration and we cannot rule out that in patients receiving oral ticagrelor, a much higher plasma exposure providing a higher mean level of inhibition could also provide a lower variability. However, ongoing trials are now investigating the efficacy of reduced dose of ticagrelor following an initial standard dose during the first month after a myocardial infarction. 30 
Conclusions
This study suggests that ticagrelor-induced platelet inhibition follows a circadian rhythm, with the lowest values reached at 13:00, independently of platelet count. These results have potential implications for antiplatelet therapy and deserve further studies in patients with coronary artery disease, as antiplatelet treatment efficacy have been shown to be completely different in this population.
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Figure 4
Circadian variation in ticagrelor-induced platelet inhibition (black) and circadian variation in platelet inhibition in the absence of pre-incubation with ticagrelor (red): median with (P25-P75) and fitted sinusoidal regression with 95% confidence interval.
